Liu Y, Li Y, Guo F, et al. Identification of HTA as a novel-specific marker for human hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2010, 136(8): 1187-1192.
[2]
Sun S, Poon RT, Lee NP, et al. Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors ( [29] Shariff MI, Ladep NG, Cox IJ, et al. Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population[J]. J Proteome Res, 2010, 9(2): 1096-1103.
[3]
Yamamoto Y, Kosaka N, Tanaka M, et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma[J]. Biomarkers, 2009, 14(7): 529-538.
Henry L, Lavabre-Bertrand T, Vercambre L, et al. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis[J]. Gut, 2009, 58(6): 833-838.
[6]
Furihata T, Sawada T, Kita J, et al. Serum alpha-fetoprotein level per tumor volume reflects prognosis in patients with hepatocellular carcinoma after curative hepatectomy[J]. Hepatogastroenterology, 2008, 55(86-87): 1705-1709.
[7]
Han GQ, Qin CY, Shu RH. The analysis of glutamyl transpeptidase gene in different type liver tissues[J]. World J Gastroenterol, 2003, 9(2): 276-280.
[8]
Suzuki M, Shiraha H, Fujikawa T, et al. Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma[J]. J Biol Chem, 2005, 280(8): 6409-6415.
Long J, Lang ZW, Wang HG, et al. Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas[J]. Hepatobiliary Pancreat Dis Int, 2010, 9(3): 296-305.
[14]
Benzoni E, Lorenzin D, Favero A, et al. Liver resection for hep-atocellular carcinoma: a multivariate analysis of factors associated with improved prognosis. The role of clinical, pathological and surgical related factors[J]. Tumori, 2007, 93(3): 264-268.
[15]
Trevisani F, D’Intino PE, Morselli-Labate AM, et al. Serum alpha2fetop rotein for diagnosis of hepatocellular carcinoma in patientswith chronic liver disease: influence of HBsAg and anti-HCV status[J]. J Hepatol, 2001, 34(4): 570-575.
[16]
Gebo KA, Chander G, Jenckes MW, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review[J]. Hepatology, 2002, 36(Suppl 1): S84-S92.
[17]
Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C: a systematic review and critical analysis [J]. Ann InternMed, 2003, 139(1): 46-50.
[18]
Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al.Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels[J]. J Clin Gastroenterol, 2000, 31(4): 302-308.
[19]
Yao DF, Jiang D, Huang Z, et al. Abnormal exp ressiom of hepatoma specific γ-glutamyl transferase and alteration of γ-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma[J]. Cancer, 2000, 88(4): 761-769.
[20]
Wu W, Yao DF, Gu LH, et al. Determination of hepatoma specific alpha-fetoprotein by a mini-column affinity chromatography method[J]. Chin J Clin Lab Sci, 2006, 24(3): 10-12.
[21]
Cheng HT, Chang YH, Chen YY, et al. AFP-L3 in chronic liver diseaseswith persistent elevation of alpha-fetoprotein[J]. J Chin Med Assoc, 2007, 70(8): 310-317.
[22]
Tamura Y, Igarashi M, Kawai H, et al. Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma[J]. Dig Dis Sci, 2010, 55(12): 3576-3583.
Wang YL, Li G, Wu D, et al. Analysis of alpha fetoprotein mRNA level on the tumor cell hematogenous spread of patients with hepatocellular carcinoma undergoing orthotopic liver transplantation[J]. Transplant Proc, 2007, 39(1): 166-168.
[25]
Masuda T, Beppu T, Horino K, et al. Preoperative tumor marker doubling time is a useful predictor of recurrence and prognosis after hepatic resection of hepatocellular carcinoma[J]. J Surg Oncol, 2010, 102(5): 490-496.
[26]
Vibert E, Azoulay D, Hoti E, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor[J]. Am J Transplant, 2010, 10(1): 129-137.
[27]
Cui R, He J, Zhang F, et al. Diagnostic value of protein induced by vitamin K absence (PIVKAⅡ) and hepatoma-specific band of serum gammaglutamyl transferase (GGTⅡ) as hepatocellular carcinoma markers complementary to alpha-fetoprotein[J]. Br J Cancer, 2003, 88(12): 1878-1882.
[28]
Wang CS, Lin CL, Lee HC, et al. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma[J]. World J Gastroenterol, 2005, 11(39): 6115-6119.
[29]
Kim do Y, Paik YH, Ahn SH, et al. PIVKA2Ⅱ is a useful tumormarker for recurrent hepatocellular carcinoma after surgical resection[J]. Oncology, 2007, 72 (Suppl 1): 52-57.
[30]
Ando E, Tanaka M, Yamashita F, et al. Diagnostic clues for recurrent hepatocellular carcinoma: comparison of tumour markers and imaging studies[J]. Eur J Gastroenterol Hepatol, 2003, 15(6): 641-648.
[31]
Lok AS, Sterling RK, Everhart JE, et al. HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma[J]. Gastroenterology, 2010, 138(2): 493-502.
